At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacogenetics, Emotional Reactivity and Smoking
In Brief
A Phase 3 clinical trial evaluating Bupropion, Varenicline, and 2 other interventions for Tobacco Use Disorder and Smoking Cessation. Completed, enrolled 646 participants across 1 site.
Detailed Summary
The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were moderated by genotype.
Study Details
Timeline
Interventions
Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
Placebo by mouth for 12 weeks.
Counseling over 8 months and telephone support calls.